Center-Authored Papers

Filters: Author is Graham, B  [Clear All Filters]
A
Adamson B, Hertz T, Duerr A, Morgan C, Keefer M, Churchyard G, Graham B, Gilbert P, Kublin J, NIAID HIV Vaccine Trials Network.  2013.  Baseline Predictors of Immunogenicity in HVTN 204. AIDS Research and Human Retroviruses. 29:A64-A65. Abstract
B
Bart P, Huang Y, Frahm N, Karuna S, Allen M, Kochar NK, Chappuis S, Gaillard J, Graham B, Pantaleo G.  2012.  rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses. Retrovirology. 9(Suppl 2):O72.
F
Fuchs JD, Morgan C, Bart P, Kochar N, Frahm N, Swann E, Gilbert P, De Rosa S, Graham B, Nabel G et al..  2012.  DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies. Retrovirology. 9(Suppl 2):P136.
H
Hammer S, Sobieszczyk M, Janes H, Gilbert P, Karuna S, Grove D, Ramirez S, Bentley C, Anude C, Mulligan M et al..  2013.  HVTN 505: Efficacy of a Multi-Gene DNA Prime/Recombinant Adeno 5 (rAd5) Vector Boost Vaccine in Men & Transgender Women (TGW) Who Have Sex with Men. AIDS Research and Human Retroviruses. 29:A172-A172. Abstract
Heit A, Schmitz F, Moore M, Gerdts S, Spearman P, Barnett S, Graham B, Robinson H, Astronomo R, Andersen-Nissen E et al..  2013.  HVTN-Tested Candidate HIV Vaccines Induce Early, Antigen-Specific Plasmablast- and Tfh-like Responses in Peripheral Blood. AIDS Research and Human Retroviruses. 29:A143-A144. Abstract
R
Rosa DSC, Frahm N, Diaz G, Newling P, Morris D, Morgan C, Graham B, Swann E, Maenza J, Duerr A et al..  2013.  No Increase in Activated T Cells and Limited Increase in Adenovirus-Specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization. AIDS Research and Human Retroviruses. 29:A180-A181. Abstract